The Medical Research Foundation of Oregon has announced the recipients of its 2009 awards for scientific leadership and innovation in Oregon. The awards were presented Nov. 10 at an invitation-only reception at Portland's Governor Hotel. The MRF ...

Giving cardiac arrest patients at least 30 seconds of CPR before assessing the need to use an electrical shock to restart their hearts is just as effective as performing 3 minutes of CPR before the assessment, a recently completed study found. The ...

Researchers in the Oregon Health & Science University Knight Cancer Institute and the Portland Veterans Affairs Medical Center have found a combination of radiation therapy and chemotherapy given before prostate removal is safe and may have the ...

The three-year, $450,000 grant – OHSU’s first from the New York-based trust – will support work by Markus Grompe, M.D., a professor in the OHSU School of Medicine Departments of Pediatrics and Molecular and Medical Genetics. Grompe has earned ...

The three-year, $450,000 grant – OHSU's first from the New York­-based trust – will support work by Markus Grompe, M.D., a professor in the OHSU School of Medicine Departments of Pediatrics and Molecular and Medical Genetics. Grompe has earned ...

Stem cells transplanted into the back of the eye mayprevent devastating eye diseases such as macular degeneration. Researchers at OHSU's Casey Eye Institute and StemCells Inc., have demonstrated that placing human neural stem cells in the back of the ...

In addition, the prevalence and severity of depression and grief among family members whose loved ones received aid in dying is no different than family members whose loved ones did not pursue physician assisted suicide. These findings are the result ...

WHAT: Internationally renowned scientist-oncologist Brian J. Druker, M.D., director of the OHSU Knight Cancer Institute, will present "The End of Cancer Is Within Reach," describing the significant progress he and colleagues have made in the fight ...

PORTLAND, Ore. — Three drugs that reduce a woman's chance of getting breast cancer also have been shown to cause adverse effects, according to a new report from the Agency for Healthcare Research and Quality (AHRQ), U.S. Department of Health & Human ...

PORTLAND, Ore. — Brian J. Druker, M.D.,whose research led to the development of Gleevec, the first targeted cancer pill to kill cancer cells while leaving healthy tissue unharmed, has been honored with one of the most distinguished awards in ...